Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

1.

When it comes to MRD, AML ≠ ALL.

Paietta E.

Blood. 2012 Aug 23;120(8):1536-7. doi: 10.1182/blood-2012-06-435081.

PMID:
22918419
[PubMed - indexed for MEDLINE]
Free Article
2.

High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.

Terwijn M, van Putten WL, Kelder A, van der Velden VH, Brooimans RA, Pabst T, Maertens J, Boeckx N, de Greef GE, Valk PJ, Preijers FW, Huijgens PC, Dräger AM, Schanz U, Jongen-Lavrecic M, Biemond BJ, Passweg JR, van Gelder M, Wijermans P, Graux C, Bargetzi M, Legdeur MC, Kuball J, de Weerdt O, Chalandon Y, Hess U, Verdonck LF, Gratama JW, Oussoren YJ, Scholten WJ, Slomp J, Snel AN, Vekemans MC, Löwenberg B, Ossenkoppele GJ, Schuurhuis GJ.

J Clin Oncol. 2013 Nov 1;31(31):3889-97. doi: 10.1200/JCO.2012.45.9628. Epub 2013 Sep 23.

PMID:
24062400
[PubMed - indexed for MEDLINE]
3.

Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group.

Loken MR, Alonzo TA, Pardo L, Gerbing RB, Raimondi SC, Hirsch BA, Ho PA, Franklin J, Cooper TM, Gamis AS, Meshinchi S.

Blood. 2012 Aug 23;120(8):1581-8. doi: 10.1182/blood-2012-02-408336. Epub 2012 May 30.

PMID:
22649108
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

[Prognosticating relapse risk based on multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia].

Wan SG, Zhao H, Sun XJ, He JJ, Su L, Xu J.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Jun;17(3):557-62. Chinese.

PMID:
19549363
[PubMed - indexed for MEDLINE]
5.

Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia.

Inaba H, Coustan-Smith E, Cao X, Pounds SB, Shurtleff SA, Wang KY, Raimondi SC, Onciu M, Jacobsen J, Ribeiro RC, Dahl GV, Bowman WP, Taub JW, Degar B, Leung W, Downing JR, Pui CH, Rubnitz JE, Campana D.

J Clin Oncol. 2012 Oct 10;30(29):3625-32. doi: 10.1200/JCO.2011.41.5323. Epub 2012 Sep 10.

PMID:
22965955
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia.

Freeman SD, Virgo P, Couzens S, Grimwade D, Russell N, Hills RK, Burnett AK.

J Clin Oncol. 2013 Nov 10;31(32):4123-31. doi: 10.1200/JCO.2013.49.1753. Epub 2013 Sep 23.

PMID:
24062403
[PubMed - indexed for MEDLINE]
7.

[Prognostic significance of minimal residual disease detected by multiparameter flow cytometry in acute myeloid leukemia].

Wang YZ, Liu YR, Zhu HH, Wu HH, Cao H, Chan Y, Hao L, Jiang B, Huang XJ.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Jun;17(3):551-6. Chinese.

PMID:
19549362
[PubMed - indexed for MEDLINE]
8.

Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group.

MRD-AML-BFM Study Group, Langebrake C, Creutzig U, Dworzak M, Hrusak O, Mejstrikova E, Griesinger F, Zimmermann M, Reinhardt D.

J Clin Oncol. 2006 Aug 1;24(22):3686-92.

PMID:
16877738
[PubMed - indexed for MEDLINE]
Free Article
9.

Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia.

Abdelhamid E, Preudhomme C, Helevaut N, Nibourel O, Gardin C, Rousselot P, Castaigne S, Gruson B, Berthon C, Soua Z, Renneville A.

Leuk Res. 2012 Mar;36(3):316-23. doi: 10.1016/j.leukres.2011.11.002. Epub 2011 Nov 29.

PMID:
22129478
[PubMed - indexed for MEDLINE]
10.

Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.

Rizzari C, Cazzaniga G, Coliva T, De Angelis C, Conter V.

Expert Rev Anticancer Ther. 2011 Sep;11(9):1391-401. doi: 10.1586/era.11.37. Review.

PMID:
21929313
[PubMed - indexed for MEDLINE]
11.

New approaches for the detection of minimal residual disease in acute myeloid leukemia.

van Rhenen A, Moshaver B, Ossenkoppele GJ, Schuurhuis GJ.

Curr Hematol Malig Rep. 2007 May;2(2):111-8. doi: 10.1007/s11899-007-0016-0. Review.

PMID:
20425359
[PubMed - indexed for MEDLINE]
12.

The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia.

Al-Mawali A, Gillis D, Lewis I.

Am J Clin Pathol. 2009 Jan;131(1):16-26. doi: 10.1309/AJCP5TSD3DZXFLCX. Review.

PMID:
19095561
[PubMed - indexed for MEDLINE]
Free Article
13.

Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol.

van der Velden VH, van der Sluijs-Geling A, Gibson BE, te Marvelde JG, Hoogeveen PG, Hop WC, Wheatley K, Bierings MB, Schuurhuis GJ, de Graaf SS, van Wering ER, van Dongen JJ.

Leukemia. 2010 Sep;24(9):1599-606. doi: 10.1038/leu.2010.153. Epub 2010 Jul 29.

PMID:
20668473
[PubMed - indexed for MEDLINE]
14.

Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia.

Venditti A, Buccisano F, Del Poeta G, Maurillo L, Tamburini A, Cox C, Battaglia A, Catalano G, Del Moro B, Cudillo L, Postorino M, Masi M, Amadori S.

Blood. 2000 Dec 1;96(12):3948-52.

PMID:
11090082
[PubMed - indexed for MEDLINE]
Free Article
15.

[Role of three-color flow cytofluorometry in the algorithm for detection of minimal residual disease in children with acute lymphoblastic and acute myeloblastic leukemia].

Savva NN, Belevtsev MV, Savitskiĭ VP, Migal' NV, Movchan LV, Aleĭnikova OV.

Klin Lab Diagn. 2009 Dec;(12):15-8. Russian.

PMID:
20140998
[PubMed - indexed for MEDLINE]
16.

Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets.

Rossi G, Minervini MM, Carella AM, de Waure C, di Nardo F, Melillo L, D'Arena G, Zini G, Cascavilla N.

Leuk Res. 2012 Apr;36(4):401-6. doi: 10.1016/j.leukres.2011.11.020. Epub 2011 Dec 21.

PMID:
22196957
[PubMed - indexed for MEDLINE]
17.

Progress of minimal residual disease studies in childhood acute leukemia.

Campana D.

Curr Hematol Malig Rep. 2010 Jul;5(3):169-76. doi: 10.1007/s11899-010-0056-8. Review.

PMID:
20467922
[PubMed - indexed for MEDLINE]
18.
19.

Minimal residual disease testing in acute leukemia by flow cytometry immunophenotyping: prognostic significance.

Ruiz-Argüelles GJ, Fernández-Lara D, Estrada-Gómez R, Manzano C, Ruiz-Delgado GJ, Pérez-Romano B, Ruiz-Argüelles A.

Lab Hematol. 2007;13(1):22-6.

PMID:
17353179
[PubMed - indexed for MEDLINE]
20.

Detection of minimal residual disease in B-lineage acute lymphoblastic leukaemia by quantitative flow cytometry.

Farahat N, Morilla A, Owusu-Ankomah K, Morilla R, Pinkerton CR, Treleaven JG, Matutes E, Powles RL, Catovsky D.

Br J Haematol. 1998 Apr;101(1):158-64.

PMID:
9576196
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk